Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution.


Journal

Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136

Informations de publication

Date de publication:
Mar 2019
Historique:
pubmed: 6 11 2018
medline: 14 6 2019
entrez: 6 11 2018
Statut: ppublish

Résumé

This study sought to clarify the molecular pathways underlying the putative evolution from lymphomatoid papulosis (LyP) to cutaneous anaplastic large-cell lymphoma (c-ALCL) and lymph node invasion (LNI). We analysed nine sequential tumours from the same patient presenting with parallel evolution of LyP (n = 3) and c-ALCL (n = 1) with LNI (n = 1), combined with systemic diffuse large B-cell lymphoma (DLBCL) (n = 4). Clonality analysis showed a common clonal T-cell origin in the five CD30+ lesions, and a common clonal B-cell origin in the four DLBCL relapses. Array-comparative genomic hybridisation and targeted next-generation sequencing analysis demonstrated relative genomic stability of LyP lesions as compared with clonally related anaplastic large-cell lymphoma (ALCL) tumours, which showed 4q and 22q13 deletions involving the PRDM8 and TIMP3 tumour suppressor genes, respectively. The three analysed CD30+ lesions showed mostly private (specific to each sample) genetic alterations, suggesting early divergence from a common precursor. In contrast, DLBCL tumours showed progressive accumulation of private alterations, indicating late divergence. Sequential cutaneous and nodal CD30+ tumours were clonally related. This suggests that LyP, c-ALCL and LNI represent a continuous spectrum of clonal evolution emerging from a common precursor of cutaneous CD30+ lymphoproliferations. Therefore, nodal ALCL tumours in the context of LyP should be considered as a form of transformation rather than composite lymphoma.

Identifiants

pubmed: 30393995
doi: 10.1111/his.13783
doi:

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

654-662

Informations de copyright

© 2018 John Wiley & Sons Ltd.

Auteurs

Luc Xerri (L)

Department of Bio-Pathology, Institut Paoli-Calmettes, Marseille, France.
Aix-Marseille University, Marseille, France.
Inserm-CNRS, CRCM, Marseille, France.

José Adélaïde (J)

Inserm-CNRS, CRCM, Marseille, France.
Department of Predictive Oncology, Institut Paoli-Calmettes, Marseille, France.

Morgan Avenin (M)

Department of Bio-Pathology, Institut Paoli-Calmettes, Marseille, France.
Aix-Marseille University, Marseille, France.

Arnaud Guille (A)

Inserm-CNRS, CRCM, Marseille, France.
Department of Predictive Oncology, Institut Paoli-Calmettes, Marseille, France.

Sebastien Taix (S)

Department of Bio-Pathology, Institut Paoli-Calmettes, Marseille, France.

Nathalie Bonnet (N)

Department of Haematology, Institut Paoli-Calmettes, Marseille, France.

Nadine Carbuccia (N)

Inserm-CNRS, CRCM, Marseille, France.
Department of Predictive Oncology, Institut Paoli-Calmettes, Marseille, France.

Séverine Garnier (S)

Inserm-CNRS, CRCM, Marseille, France.
Department of Predictive Oncology, Institut Paoli-Calmettes, Marseille, France.

Lenaïg Mescam (L)

Department of Bio-Pathology, Institut Paoli-Calmettes, Marseille, France.

Anne Murati (A)

Department of Bio-Pathology, Institut Paoli-Calmettes, Marseille, France.

Max Chaffanet (M)

Inserm-CNRS, CRCM, Marseille, France.
Department of Predictive Oncology, Institut Paoli-Calmettes, Marseille, France.

Diane Coso (D)

Department of Haematology, Institut Paoli-Calmettes, Marseille, France.

Reda Bouabdallah (R)

Department of Haematology, Institut Paoli-Calmettes, Marseille, France.

François Bertucci (F)

Aix-Marseille University, Marseille, France.
Inserm-CNRS, CRCM, Marseille, France.
Department of Predictive Oncology, Institut Paoli-Calmettes, Marseille, France.

Daniel Birnbaum (D)

Aix-Marseille University, Marseille, France.
Inserm-CNRS, CRCM, Marseille, France.
Department of Predictive Oncology, Institut Paoli-Calmettes, Marseille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH